Why Most Brightening Serums Only Address Half the Problem

Word Count: ~1,050

If your brightening serum targets tyrosinase alone, it is working on one enzyme in a system controlled by dozens. That is the clinical reality most skincare brands leave out of their marketing.

Dr Alison Jamieson has spent over forty years treating pigmentation in one of the harshest UV environments on earth — Queensland, Australia. Her perspective on the brightening category is blunt: most products address the symptom while ignoring the signal.

Your skin runs two pigmentation systems, not one

The first is constitutive pigmentation — your baseline skin colour, determined by genetics. The second is facultative pigmentation — the darker patches, sun spots, and uneven tone that develop in response to UV exposure, hormonal shifts, and inflammation.

Most brightening ingredients focus entirely on the facultative side, and most of those zero in on a single enzyme: tyrosinase. Vitamin C inhibits it. Arbutin inhibits it. Kojic acid inhibits it. The problem is that tyrosinase is only one player in a much larger operation.

Dr Jamieson describes it as addressing the factory floor while leaving the manager's office untouched. The enzyme does the work, but something upstream is giving the orders.

MITF: the master transcription factor

That something is MITF — Micropthalmia-associated Transcription Factor. MITF sits upstream of every melanogenic enzyme in the pathway. It does not just control tyrosinase; it regulates TRP-1 and TRP-2 as well. When MITF is active, it switches on the entire pigmentation production line. When it is suppressed, the whole system slows.

This is why Dr Jamieson formulated the Aliange Brightening Serum around Oligopeptide-68 — a peptide that mimics TGF-beta to downregulate MITF itself. Rather than inhibiting one enzyme at one stage, it addresses the master controller that governs all of them.

In a 2016 randomised, double-blind clinical trial (Pratchyapurit et al.), an Oligopeptide-68 formulation matched or outperformed 4% hydroquinone across 38 patients over 12 weeks, with 76.3% showing moderate improvement and no severe adverse reactions. Hydroquinone, by contrast, carries risks significant enough that it is banned for over-the-counter sale in the EU, Japan, and Australia due to concerns including ochronosis and rebound hyperpigmentation.

Licorice root confirms the upstream approach

Dr Jamieson's formulation also includes Glycyrrhiza Glabra — licorice root extract — and recent research reinforces why. A 2025 study confirmed that glabridin, the key bioactive in licorice, targets MITF through the CREB/CRTC1 signalling pathway. This is a separate mechanism to Oligopeptide-68, but the destination is the same: MITF suppression.

In laboratory studies, glabridin demonstrated tyrosinase inhibition at concentrations of 0.1–1.0 micrograms per millilitre. In vitro comparisons have shown it to be up to 16 times more potent than hydroquinone at inhibiting tyrosinase activity.

⚠️ Note: The 16x in vitro comparison is a laboratory finding, not a clinical outcome measure. In vitro potency does not translate directly to real-world efficacy. This claim requires Dr Jamieson's review before use in any customer-facing marketing context.

What makes this relevant is not the headline number — it is the fact that two ingredients in the same formulation are suppressing MITF through different biochemical routes. Redundancy at the control level is deliberate. If one pathway is partially blocked by individual variation or environmental factors, the other continues to function.

Why single-target brightening fails over time

The limitation of tyrosinase-only inhibitors is well documented clinically. A patient may see initial improvement as the enzyme is partially suppressed, but MITF continues to signal for melanin production. The body compensates. New tyrosinase is synthesised to replace what has been inhibited. Pigmentation returns.

This is the rebound effect that frustrates so many people. They use a vitamin C serum for eight weeks, see some improvement, plateau, and assume the product stopped working. In many cases, the product never stopped working — it simply never addressed the root signal.

Dr Jamieson's approach within the Aliange Protocol is to layer interventions across the entire pathway: MITF suppression at the top (Oligopeptide-68 and licorice root), melanosome transfer interruption in the middle (niacinamide blocks 35–68% of melanin delivery to the skin surface), and accelerated surface renewal at the bottom (a calibrated AHA blend of lactic, glycolic, malic, tartaric, and citric acids).

This is not a single-ingredient solution. It is a system designed to address pigmentation at every stage where intervention is possible.

The role of SPF in any brightening protocol

No brightening protocol functions without sun protection. UV radiation is the primary trigger for facultative pigmentation — the very system most people are trying to correct. Applying a brightening serum without daily SPF is clinically counterproductive: you are attempting to suppress a signal while the strongest activator of that signal goes unchecked.

The landmark Nambour Trial (Hughes et al., 2013) — a randomised controlled trial of 903 Australians over 4.5 years — demonstrated that daily SPF 15 use resulted in 24% less clinical photoaging compared to discretionary use. In Queensland, where UV intensity is up to 15% higher than equivalent Northern Hemisphere latitudes, this is not optional. It is the foundation.

Dr Jamieson recommends the Aliange Day Cream SPF 15 as the non-negotiable morning step in any pigmentation-focused protocol.

What to expect

Based on clinical data and the mechanism of action of each active:

Weeks 1–2: AHAs begin shedding surface pigment. Texture improves first. Weeks 2–4: Niacinamide interrupts melanosome transfer. Complexion starts evening. Weeks 4–8: Oligopeptide-68 MITF suppression reaches visible effect. This is where most patients report noticeable improvement. Weeks 8–12: Cumulative multi-pathway effect is maximised. In manufacturer studies, 87% of subjects reported more uniform skin tone at 56 days.

These are not promises. They are the clinical timeline supported by the published research behind each active ingredient.

The Aliange Brightening Serum ($100, 50ml) is available at aliange.com.au. To find the protocol indicated for your skin concern, take the 60-second skin quiz.

Dr Alison Jamieson (MBBS, FRACGP, Dip Derm) is the clinical founder of Aliange and has over 40 years of experience in cosmetic medicine.